|
Drug
company Merck is seeking approval from the FDA to sell their cholesterol
drug Mevacor over the counter. The attempt marks the company's
second try at selling their drug without a prescription.
As it stands, only allergy pills and stomach acid remedies have
made the switch from prescription to over-the-counter status. The
difference is that cholesterol-lowering drugs, unlike the other
two categories, are geared toward a chronic condition that has no
symptoms.
This is one reason why doctors who believe over-the-counter drugs
should be used for short-term conditions that patients can diagnose
themselves are highly skeptical of the potential switch.
Further, cholesterol drugs, which make up the top-selling category
of drugs in the United States (they brought in $14 billion in sales
in 2003), are known to raise the risk of liver, kidney and muscle
problems.
Previously, the FDA recommended against allowing Mevacor to be
sold without a prescription, saying they needed more information
about whether consumers would use the drug in the right manner.
Since then, Merck reportedly conducted a study showing that consumers
are able to make the correct decisions regarding the drug.
If Mevacor is granted over-the-counter
status:
- Merck has prepared in-store materials to educate consumers on
whether or not they should take the drug
- Consumers would need a blood test to identify their cholesterol
level
- Consumers would need to learn the risk factors for heart disease
- The drug would be marketed to people with at least one risk
factor for heart disease and a "bad" LDL cholesterol
level in the 130 to 170 range
- The drug, in a 20-milligram dose, would cost about $1 a day
Bristol-Myers Squibb also intends to seek over-the-counter status
for its cholesterol drug Pravachol.
USA
Today December 28, 2004
|